Bright Minds Biosciences Shares to Commence Trading on the OTCQB Venture Market on May 17, 2021

Press Release

VANCOUVER, British Columbia, May 17, 2021 (GLOBE NEWSWIRE) — Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (CSE:DRUG) (OTCQB:BMBIF), a biotechnology company focused on developing novel transformative treatments for neuropsychiatry disorders, epilepsy and pain, today announced that its shares will commence trading on the OTCQB® Venture Market (the “OTCQB”) on May 17, 2021, under…

Bright Minds Biosciences to Present at the Benzinga Global Small Cap Conference

Press Release

VANCOUVER, British Columbia, May 11, 2021 (GLOBE NEWSWIRE) — Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (CSE:DRUG), a biotechnology company focused on developing novel transformative treatments for neuropsychiatry disorders, epilepsy and pain, today announced that Ian McDonald, Chief Executive Officer, and Dr. Gideon Shapiro Ph.D, Vice President of Discovery, will be presenting at…

Bright Minds Biosciences Announces Stock Option Grants

Press Release

Vancouver, British Columbia, May 4, 2021 – Bright Minds Biosciences Inc. (CSE:DRUG) (“Bright Minds” or the “Company”) announces that it has granted an aggregate of 240,000 stock options (the “Options”) to consultants of the Company to purchase 240,000 common shares (the “Shares”)in the capital of the Company pursuant to the Company’s share option plan. The…